Company
LON:EVE
We believe in the perfect start. Every great day starts the night before. Good sleep and great starts are too important to be elitist. For too long, mattresses have been sold through expensive stores at massively inflated prices. So we set out to create eve. A mattress that is simply beautiful and beautifully simple, and available to everyone at a surprisingly fair price.
113 stories · page 3 of 6
Archive
Evgen Pharma 6.45p £17.7m (LON:EVG) The clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, notes the publication of data in preclinical models of glioblastoma (GBM) genera
The update was provided in the scientific journal 'Pharmaceuticals'
Archive
Tekmar 44.5p £23m (LON:TGP) The provider of technology and services for the global offshore energy markets, is pleased to announce it has successfully delivered the final batch of Cable Protection Systems (CPS) for Ørsted's Hornsea Two Offs
In the in vitro experiments, the company said SFX-01 demonstrated inhibition of glioblastoma cell growth, confirming work previously carried out elsewhere
The drug company said the OD designation is part of a wider strategy to access the US market
It is making an orphan drug application in the US. Preclinical research, meanwhile, has flagged the potential of SFX-01 in a form of leukaemia
Chief executive, Dr Huw Jones, said he and the team were both surprised and disappointed by the outcome
“Over the last 12 months Evgen has substantially strengthened its senior team, made considerable progress across all areas of its business, raised significant funding to accelerate the development of its therapeutic programmes and concluded
The group is developing treatment for brain and breast tumours
Evgen is a clinical stage drug development company focused on the treatment of cancer, inflammation and acute respiratory distress syndrome
Scientists found that sulforaphane, the active ingredient in the company’s multi-purpose treatment, SFX-01, prevents virus-induced cell death sparked by variants of the SARS-CoV-2 virus and another unnamed coronavirus
Dr Helen Kuhlman has held senior roles at Development Bank of Wales, Innovate UK and Chronos Therapeutics Ltd
Archive
A look at the major movers on the London market on Thursday
As part of the process, Dundee University has decided to review the top-level unblinded data in a preliminary assessment of possible efficacy
SFX-01, the company’s lead compound. has potential applications in cancers, inflammation and acute respiratory distress syndrome
The firm said it is an important milestone bringing it a step closer to receiving the initial data from the trial
The company said it has raised £10mln through a share placing and will aim to raise an additional £1mln through an open offer to qualifying shareholders
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
The latest research was carried out by Professor Philip Eaton, of Queen Mary University of London
The sleep wellness retailer cut losses by 81% in 2020
